Synairgen developing COPD treatment to hold off further viral damage

Richard Marsden, CEO at Synairgen, discusses the company’s Phase II clinical trial with a new inhaled antiviral protein treatment developed specifically for COPD patients whose lung disease is greatly exacerbated with a cold or flu virus. The drug and the delivery method boost the patients’ antiviral immune response at a critical juncture. Marsden attended BIO-Europe to talk to large and midsize pharma companies as potential partners in further trials as well as in future global development.